Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1947 1
1951 2
1952 2
1953 3
1954 1
1955 1
1956 1
1959 1
1960 2
1961 2
1962 2
1964 2
1965 2
1966 1
1967 1
1968 2
1969 3
1970 5
1971 8
1972 1
1973 3
1974 10
1975 13
1976 4
1977 4
1978 7
1979 8
1980 8
1981 11
1982 19
1983 19
1984 17
1985 17
1986 20
1987 22
1988 21
1989 23
1990 17
1991 17
1992 45
1993 48
1994 39
1995 36
1996 59
1997 49
1998 38
1999 44
2000 51
2001 53
2002 60
2003 58
2004 82
2005 70
2006 80
2007 73
2008 64
2009 73
2010 81
2011 69
2012 86
2013 89
2014 87
2015 90
2016 82
2017 76
2018 77
2019 73
2020 114
2021 113
2022 109
2023 97
2024 13

Text availability

Article attribute

Article type

Publication date

Search Results

2,361 results

Results by year

Filters applied: . Clear all
Page 1
Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML.
Perl AE, Martinelli G, Cortes JE, Neubauer A, Berman E, Paolini S, Montesinos P, Baer MR, Larson RA, Ustun C, Fabbiano F, Erba HP, Di Stasi A, Stuart R, Olin R, Kasner M, Ciceri F, Chou WC, Podoltsev N, Recher C, Yokoyama H, Hosono N, Yoon SS, Lee JH, Pardee T, Fathi AT, Liu C, Hasabou N, Liu X, Bahceci E, Levis MJ. Perl AE, et al. Among authors: yokoyama h. N Engl J Med. 2019 Oct 31;381(18):1728-1740. doi: 10.1056/NEJMoa1902688. N Engl J Med. 2019. PMID: 31665578 Clinical Trial.
Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results.
Lesokhin AM, Tomasson MH, Arnulf B, Bahlis NJ, Miles Prince H, Niesvizky R, Rodrίguez-Otero P, Martinez-Lopez J, Koehne G, Touzeau C, Jethava Y, Quach H, Depaus J, Yokoyama H, Gabayan AE, Stevens DA, Nooka AK, Manier S, Raje N, Iida S, Raab MS, Searle E, Leip E, Sullivan ST, Conte U, Elmeliegy M, Czibere A, Viqueira A, Mohty M. Lesokhin AM, et al. Among authors: yokoyama h. Nat Med. 2023 Sep;29(9):2259-2267. doi: 10.1038/s41591-023-02528-9. Epub 2023 Aug 15. Nat Med. 2023. PMID: 37582952 Free PMC article. Clinical Trial.
Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1-RUNX1T1 and CBFB-MYH11.
Ishikawa Y, Kawashima N, Atsuta Y, Sugiura I, Sawa M, Dobashi N, Yokoyama H, Doki N, Tomita A, Kiguchi T, Koh S, Kanamori H, Iriyama N, Kohno A, Moriuchi Y, Asada N, Hirano D, Togitani K, Sakura T, Hagihara M, Tomikawa T, Yokoyama Y, Asou N, Ohtake S, Matsumura I, Miyazaki Y, Naoe T, Kiyoi H. Ishikawa Y, et al. Among authors: yokoyama h. Blood Adv. 2020 Jan 14;4(1):66-75. doi: 10.1182/bloodadvances.2019000709. Blood Adv. 2020. PMID: 31899799 Free PMC article.
Cardiovascular surgery training in Japan.
Tanemoto K, Yokoyama H, Okita Y, Ueda Y, Takamoto S, Yaku H, Bando K, Hashimoto K. Tanemoto K, et al. Among authors: yokoyama h. J Thorac Cardiovasc Surg. 2022 Jan;163(1):166-175.e5. doi: 10.1016/j.jtcvs.2020.12.090. Epub 2020 Dec 26. J Thorac Cardiovasc Surg. 2022. PMID: 33589313 Free article. No abstract available.
Prevalence of anemia in patients with chronic kidney disease in Japan: A nationwide, cross-sectional cohort study using data from the Japan Chronic Kidney Disease Database (J-CKD-DB).
Sofue T, Nakagawa N, Kanda E, Nagasu H, Matsushita K, Nangaku M, Maruyama S, Wada T, Terada Y, Yamagata K, Narita I, Yanagita M, Sugiyama H, Shigematsu T, Ito T, Tamura K, Isaka Y, Okada H, Tsuruya K, Yokoyama H, Nakashima N, Kataoka H, Ohe K, Okada M, Kashihara N. Sofue T, et al. Among authors: yokoyama h. PLoS One. 2020 Jul 20;15(7):e0236132. doi: 10.1371/journal.pone.0236132. eCollection 2020. PLoS One. 2020. PMID: 32687544 Free PMC article.
Improvement of glycaemic control and treatment satisfaction by switching from liraglutide or dulaglutide to subcutaneous semaglutide in patients with type 2 diabetes: A multicentre, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 1 study).
Takahashi Y, Nomoto H, Yokoyama H, Takano Y, Nagai S, Tsuzuki A, Cho KY, Miya A, Kameda H, Takeuchi J, Taneda S, Kurihara Y, Atsumi T, Nakamura A, Miyoshi H; SWITCH-SEMA 1 study group. Takahashi Y, et al. Among authors: yokoyama h. Diabetes Obes Metab. 2023 Jun;25(6):1503-1511. doi: 10.1111/dom.14998. Epub 2023 Feb 28. Diabetes Obes Metab. 2023. PMID: 36722623 Clinical Trial.
Elucidation of the Role of FAM210B in Mitochondrial Metabolism and Erythropoiesis.
Suzuki C, Fujiwara T, Shima H, Ono K, Saito K, Kato H, Onodera K, Ichikawa S, Fukuhara N, Onishi Y, Yokoyama H, Nakamura Y, Igarashi K, Harigae H. Suzuki C, et al. Among authors: yokoyama h. Mol Cell Biol. 2022 Dec 15;42(12):e0014322. doi: 10.1128/mcb.00143-22. Epub 2022 Nov 14. Mol Cell Biol. 2022. PMID: 36374104 Free PMC article.
Tough hydrogels with rapid self-reinforcement.
Liu C, Morimoto N, Jiang L, Kawahara S, Noritomi T, Yokoyama H, Mayumi K, Ito K. Liu C, et al. Among authors: yokoyama h. Science. 2021 Jun 4;372(6546):1078-1081. doi: 10.1126/science.aaz6694. Science. 2021. PMID: 34083486
Wound repair, remodeling, and regeneration.
Bando T, Yokoyama H, Nakamura H. Bando T, et al. Among authors: yokoyama h. Dev Growth Differ. 2018 Aug;60(6):303-305. doi: 10.1111/dgd.12566. Dev Growth Differ. 2018. PMID: 30133712 No abstract available.
2,361 results